SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending amidst community discussion about a recent dip attributed to a report of security flaws in its software, which some investors believe is a buying opportunity due to the company's rebuttal and potential for a Monday recovery. The community is debating whether the dip is a result of a coordinated short attack or an overreaction, with many expressing confidence in Palantir's long-term prospects within the growing AI sector.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending due to community excitement around its potential connection to rare earth mineral deals with the Trump administration, reminiscent of similar situations with LAC.  The community is actively speculating on upcoming news and the stock's potential, drawing parallels to other rare earth mineral stocks that have surged following government interest. Some investors are also pointing out the valuation discrepancy between CRML and EULIF.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

WEEDCOIN is gaining attention, with community members highlighting its website and Dexscreener link. Advocates express optimism, noting consistent growth, solid volume, and strong community support, while drawing parallels to the broader cultural significance of cannabis. The coin is promoted with the slogan "Like Bitcoin But Way Higher".

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is trending amid speculation of a potential government stake in the company, similar to previous investments in the rare earth sector. Community chatter revolves around the possibility of a Trump administration deal and its potential impact on the stock price, with comparisons being drawn to MP Materials' government-backed surge. Despite some concerns about potential dilution, the focus remains on the company's strategic positioning in the rare earth magnet supply chain and its importance to national security.

The project is a groundbreaking memecoin powered by advanced AI that interacts with the community across platforms like X (formerly Twitter). The AI generates unique content, including text, images, videos, music, and animations, all based on current trends. As it learns from user interactions, the AI becomes more responsive, providing engaging and dynamic experiences. Holders are rewarded with exclusive content, voting rights, and governance opportunities, creating an interactive ecosystem that evolves with the community.

Shadow AI

Shadow AI ($SHADOAI) is trending as the community expresses bullish sentiment and anticipates a potential breakout. Discussions highlight its connection to the Solana blockchain and other popular tokens like PEPE and SHIB. The community frames Shadow AI as a hidden gem with significant upside potential in the AI crypto space.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai ($AI) is trending amid discussion of buyout rumors, potential M&A targets, and analyst opinions, with some traders citing a Wedbush analyst naming it a takeover target and Reddit threads fueling speculation. Despite its association with the AI sector, some community members are questioning its growth strategy and comparing it to competitors. Others express optimism based on its ticker symbol and potential for government contracts.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending as excitement builds around quantum computing's potential, fueled by contract wins and overall sector momentum. Community members are actively discussing potential catalysts, including government contracts and big tech partnerships, with some comparing QBTS to NVDA in its early stages. Despite some skepticism regarding valuation, the stock is experiencing increased attention and trading volume.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amidst discussions about potential market manipulation and price targets, with the community debating its true valuation and reacting to volatile price swings. Some traders are taking advantage of the dips while others express frustration over missed profit opportunities, remaining optimistic about long-term growth in the telehealth sector. Recent news and developments may have contributed to the stock's activity.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is trending as investor interest surges, fueled by bullish analyst coverage and eased risk aversion in the market. The community is actively discussing the company's potential shift towards crypto/blockchain applications and a recent price target upgrade. Some traders are eyeing potential short squeezes, while others remain skeptical about the company's revenue and valuation compared to peers like $IONQ and $QBTS.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is trending as investors discuss the stock's persistent downtrend despite positive fundamentals, including profitability and revenue growth; the community is debating potential catalysts, such as a buyout or strategic acquisition, while expressing frustration with management's actions and overall market manipulation impacting the stock's valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AstraZeneca (AZN) announced on Wednesday that its late-stage trial of Fasenra in patients with chronic obstructive pulmonary disease (COPD) did not achieve statistical significance in the primary endpoint of controlling flare-ups.COPD, also called Smoker’s Disease, is a debilitating, irreversible, and progressive disease whose exacerbations are life-threatening and can cause irreversible lung damage and even death. According to AstraZeneca, it affects 391 million people globally.The safety and tolerability of the drug in the recent trial were consistent with the known profile of the medicine. The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.astrazeneca.com/media-centre/press-releases/2025/update-on-resolute-phase-iii-trial.html">stated</a> that it will analyze the data further to understand the results.Shares of the company slipped 0.3% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AZN">AZN stock</a> fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume fell from ‘normal’ to ‘low’ levels.<figure class="image"><img style="aspect-ratio:572/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_17_at_7_28_11_AM_png_b16313a518.webp" alt="AZN's Sentiment Meter and Message Volume as of 7:28 a.m. ET on Sept. 17, 2025 | Source: Stocktwits" width="572" height="62"><figcaption>AZN's Sentiment Meter and Message Volume as of 7:28 a.m. ET on Sept. 17, 2025 | Source: Stocktwits</figcaption></figure> The study was aimed at evaluating the efficacy and safety of 100 mg of Fasenra in people with moderate to very severe COPD with a history of frequent COPD exacerbations and an elevated blood eosinophil count. The company enrolled patients in the trial with a history of at least two COPD exacerbations in the year before enrollment and who were current or former smokers. Patients were randomized to receive either a placebo or Fasenra while remaining on their existing therapy.“COPD, which remains a leading cause of death worldwide, is a complex, heterogeneous disease and we continue to advance other promising approaches in our pipeline to address the unmet needs of patients,” company executive Sharon Barr saidFasenra is already used to treat severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis in several countries. According to AstraZeneca, over 150,000 patients worldwide are currently taking Fasenra. In the first half of 2025, Fasenra generated $920 million in revenue, representing an 18% year-over-year increase.Separately, the company also <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.astrazeneca.com/media-centre/press-releases/2025/saphnelo-met-primary-endpoint-in-tulip-sc.html">announced</a> that its late-stage trial evaluating subcutaneous Saphnelo in patients with systemic lupus erythematosus (SLE) met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in disease activity compared to placebo. SLE is an autoimmune disease in which the immune system attacks healthy tissue in the body. It is estimated to impact over 3.4 million people globally.AZN stock is up by 18% this year and down by about 1% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/x4-pharma-to-halve-headcount-amid-efforts-to-complete-neutropenia-trial/chDGnJwRd6P">X4 Pharma To Halve Headcount Amid Efforts To Complete Neutropenia Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the AstraZeneca logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

AstraZeneca Says Asthma Drug Failed Trial In Smoker’s Disease

The company stated that the safety and tolerability of the drug in the recent trial were consistent with the known profile of the medicine, and added that it will analyze the data further to understand the results.

Equity

The company stated that the safety and tolerability of the drug in the recent trial were consistent with the known profile of the medicine, and added that it will analyze the data further to understand the results.


Marvell Technology (MRVL) plunged more than 17% at market open on Friday after issuing weaker-than-expected third-quarter guidance in its fiscal second-quarter report released late Thursday, which drew swift price target cuts and&nbsp;a ratings downgrade from Wall Street.<a href="http://stocktwits.com/symbol/MRVL">Marvell’s stock</a> was among the top trending tickers on Stocktwits at the time of writing. Despite the dip in its stock price, retail sentiment around the company surged to ‘extremely bullish’ from ‘bullish’ with chatter rising to ‘extremely high’ from ‘low’ levels over the past day, according to platform data.Bank of America downgraded&nbsp;Marvell’s stock to ‘Neutral’ from ‘Buy’, lowering its price target to $78 from $90, as per TheFly. The firm cited uncertainty surrounding Marvell’s role in Microsoft’s (MSFT) Maia AI accelerator and its share of Amazon’s (AMZN) next-generation 3nm project.Morgan Stanley trimmed its target on the stock to $76 from $80 while keeping an ‘Equal Weight’ rating. The firm noted that while guidance was largely in line once the sale of Marvell’s automotive Ethernet business was factored in, the data center segment “disappointed.” Morgan Stanley added that it was not surprised by the business’s “lumpiness,” but said it was unexpected that the ASIC full-year outlook continues to decline even as demand for Amazon’s Trainium processors strengthens elsewhere.&nbsp;UBS, which lowered its price target to $95 from $110,&nbsp; also pointed to “lumpiness” in Marvell’s business.&nbsp;Needham echoed similar concerns about Marvell’s next-gen XPU contracts with Amazon and Microsoft as it lowered its price target to $80 from $85, but maintained its ‘Buy’ rating on the stock.Marvell’s stock has fallen more than 41% this year and is down around 7% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-revokes-intel-samsung-sk-hynix-waivers-on-china-chip-equipment/chtTKpgRdNh">US Revokes Intel, Samsung, SK Hynix Waivers On China Chip Equipment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Marvell Hit With Downgrade, Price Target Cuts As Analysts Flag Uncertainty In Microsoft, Amazon AI Deals

Bank of America downgraded Marvell’s stock to ‘Neutral’ from ‘Buy’, lowering its price target to $78 from $90.

Should Invesco NASDAQ 100 ETF (QQQM) Be on Your Investing Radar?

3 Reasons Why Nasdaq ETFs Hit a Record High 

The Nasdaq hit a record high despite tariffs, as Apple's $100B U.S. push, Fed rate cut talks and chip exemptions fuel tech optimism.

Nasdaq ETF (QQQM) Hits New 52-Week High

QQQM surges to a new 52-week high, fueled by tech strength and AI-driven earnings momentum in Nasdaq.


Will Nasdaq ETFs Continue Their Rally Going Into Q2 Earnings?

QQQ, QQQM, QQEW, QQQJ and QQQE surge as Nasdaq hits highs on earnings momentum, AI optimism and rate cut hopes.

High-Yield ETFs: Big Payouts, Bigger Trade-Offs?

Here's what investors should know about covered-call single-stock ETFs.

AstraZeneca (AZN) on Friday <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-enters-into-collaboration-with-cspc.html">announced</a> a strategic research collaboration with China-based CSPC Pharmaceuticals Group to advance the development of oral drug candidates with the potential to treat multiple chronic diseases.Under the deal, the companies have also agreed to develop a pre-clinical small-molecule oral therapy for immunological diseases.The research will be carried out by CSPC in Shijiazhuang City and will utilize their AI-driven drug discovery platform, which uses AI to analyse the binding patterns of target proteins with existing compound molecules. The AI also helps conduct targeted optimization with the intent of selecting highly effective small molecules with excellent developability.CSPC will receive an upfront payment of $110 million as part of the agreement, and is eligible to receive up to $1.62 billion in potential development milestone payments and up to $3.6 billion in sales milestone payments.CSPC can also receive potential single-digit royalties based on annual net sales of the products.AstraZeneca, meanwhile, will have the right to exercise options for exclusive licenses to develop and commercialize worldwide candidates identified under the agreement.In March, AstraZeneca announced a $2.5 billion investment in a research and development hub in Beijing. The new agreement will further the company’s presence in China, AstraZeneca said.On Stocktwits, retail sentiment around AstraZeneca stayed within the ‘neutral’ territory over the past 24 hours while message volume rose from ‘low’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:1260/132;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_13_at_7_54_25_AM_png_1341b85d61.webp" alt="AZN's Sentiment Meter and Message Volume as of 7:54 a.m. ET on Jun 13, 2025 | Source: Stocktwits" width="1260" height="132"><figcaption>AZN's Sentiment Meter and Message Volume as of 7:54 a.m. ET on Jun 13, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/AZN">AZN stock</a> is up by about 14% this year but down by nearly 6% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-launches-upgraded-model-s-x-in-us-raises-prices-5000-dollars/chlicMCRRGy">Tesla Launches Upgraded Model S, X In US, Raises Prices On All Variants By $5,000</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AstraZeneca Inks $5.3B Deal With CSPC Pharma For Developing New Oral Drug Candidate, But Retail’s In No Mood To Cheer

CSPC will receive an upfront payment of $110 million as part of the agreement, and is eligible to receive up to $1.62 billion in potential development milestone payments and up to $3.6 billion in sales milestone payments.

Invesco Exchange-Traded Fund Trust II - Invesco NASDAQ 100 ETF

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

QQQM
Invesco NASDAQ 100 ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest QQQM News

QQQM Invesco NASDAQ 100 ETF